Astaxanthin conjugated polypyrrole nanoparticles as a multimodal agent for photo-based therapy and imaging

Bharathiraja, Subramaniyan; Manivasagan, Panchanathan; Oh, Yunok; Moorthy, Madhappan Santha; Seo, Hansu; Bui, Nhat Quang; Oh, Junghwan

doi:10.1016/j.ijpharm.2016.12.020

Cited by 30 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoparticle-based drug delivery systems have been used to encapsulate ATX to avoid the drawbacks mentioned above. Recently, many drug delivery systems and preparation methods have been explored to improve stability and water-solubility, such as DNA/chitosan nanoparticles [17], polyrrole nanoparticles [18], gold nanoparticles [19], nanoliposomes [20], nanopowders, and nanodispersions [20]. In the present study, we fabricated ATX-LPN by using an emulsion and evaporation technique.…”

Section: Discussionmentioning

confidence: 99%

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): assessment of potential otoprotective effects

Chen

Tong

et al. 2020

J Nanobiotechnol

View full text Add to dashboard Cite

Background: Ototoxicity is one of the major side effects of platinum-based chemotherapy, especially cisplatin therapy. To date, no FDA approved agents to alleviate or prevent this ototoxicity are available. However, ototoxicity is generally believed to be produced by excessive generation of reactive oxygen species (ROS) in the inner ear, thus leading to the development of various antioxidants, which act as otoprotective agents. Astaxanthin (ATX) is an interesting candidate in the development of new therapies for preventing and treating oxidative stress-related pathologies, owing to its unique antioxidant capacity. Methods and results:In this study, we aimed to evaluate the potential antioxidant properties of ATX in the inner ear by using the HEI-OC1 cell line, zebrafish, and guinea pigs. Because ATX has poor solubility and cannot pass through round window membranes (RWM), we established lipid-polymer hybrid nanoparticles (LPN) for loading ATX. The LPN enabled ATX to penetrate RWM and maintain concentrations in the perilymph in the inner ear for 24 h after a single injection. ATX-LPN were found to have favorable biocompatibility and to strongly affect cisplatin-induced generation of ROS, on the basis of DCFHDA staining in HEI-OC1 cells. JC-1 and MitoTracker Green staining suggested that ATX-LPN successfully reversed the decrease in mitochondrial membrane potential induced by cisplatin in vitro and rescued cells from early stages of apoptosis, as demonstrated by FACS stained with Annexin V-FITC/PI. Moreover, ATX-LPN successfully attenuated OHC losses in cultured organ of Corti and animal models (zebrafish and guinea pigs) in vivo. In investigating the protective mechanism of ATX-LPN, we found that ATX-LPN decreased the expression of pro-apoptotic proteins (caspase 3/9 and cytochrome-c) and increased expression of the anti-apoptotic protein Bcl-2. In addition, the activation of JNK induced by CDDP was up-regulated and then decreased after the administration of ATX-LPN, while P38 stayed unchanged. Conclusions:To best of our knowledge, this is first study concluded that ATX-LPN as a new therapeutic agent for the prevention of cisplatin-induced ototoxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): assessment of potential otoprotective effects

Chen

Tong

et al. 2020

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Human breast cancer in vitro Astaxanthin 808 nm, 300 mW.cm À2 6 h DLI PA @ 808 nm to monitor PPy@BSA-Astx US signal production Passive targeting (141) boundaries and reduce operator variability is currently being pursued which will further the utility of USI in PDT treatment monitoring (119). While US imaging is ubiquitously available for patient care, PA imaging is also making strides in the clinical realm in characterizing prostate, breast and skin cancer lesions (120).…”

Section: Mba-md-231mentioning

confidence: 99%

Role of Ultrasound and Photoacoustic Imaging in Photodynamic Therapy for Cancer

Hester

Kuriakose

Nguyen

et al. 2020

Photochem & Photobiology

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a phototoxic treatment with high spatial and temporal control and has shown tremendous promise in the management of cancer due to its high efficacy and minimal side effects. PDT efficacy is dictated by a complex relationship between dosimetry parameters such as the concentration of the photosensitizer at the tumor site, its spatial localization (intracellular or extracellular), light dose and distribution, oxygen distribution and concentration, and the heterogeneity of the inter‐ and intratumoral microenvironment. Studying and characterizing these parameters, along with monitoring tumor heterogeneity pre‐ and post‐PDT, provides essential data for predicting therapeutic response and the design of subsequent therapies. In this review, we elucidate the role of ultrasound (US) and photoacoustic imaging in improving PDT‐mediated outcomes in cancer—from tracking photosensitizer uptake and vascular destruction, to measuring oxygenation dynamics and the overall evaluation of tumor responses. We also present recent advances in multifunctional theranostic nanomaterials that can improve either US or photoacoustic imaging contrast, as well as deliver photosensitizers specifically to tumors. Given the wide availability, low‐cost, portability and nonionizing nature of US and photoacoustic imaging, together with their capabilities of providing multiparametric morphological and functional information, these technologies are thusly inimitable when deployed in conjunction with PDT.

show abstract

“…Nanoparticle-based drug delivery systems have been used to encapsulate ATX to avoid the drawbacks mentioned above. Recently, many drug delivery systems and preparation methods have been explored to improve stability and water-solubility, such as DNA/chitosan nanoparticles [19] , polyrrole nanoparticles [20] , gold nanoparticles [21] , nanoliposomes [22] , nanopowders, and nanodispersions [23] . In the present study, we fabricated ATX-LPN by using an emulsion and evaporation technique.…”

Section: Atx-lpn Partially Restored Cddp-induced Hearing Loss In Abr mentioning

confidence: 99%

“…The protective effect of ATX-LPN in terms of morphology was verified by rescuing OHCs in cultured cochlear explants. We then evaluated auditory function and found that hearing was restored by [20][21][22][23][24][25][26][27][28][29][30] dB SPL at a wide range of frequencies after ATX/ATX-LPN administration. Although greater CDDPinduced damage exists in the high-frequency area in both animals and humans [46] , a better restoration of hearing was observed.…”

Section: Atx-lpn Partially Restored Cddp-induced Hearing Loss In Abr mentioning

confidence: 99%

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN) Assessment of potential otoprotective effects

Chen

Tong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Ototoxicity is one of the major side effects of platinum-based chemotherapy, especially cisplatin therapy. To date, no FDA approved agents to alleviate or prevent this ototoxicity are available. However, ototoxicity is generally believed to be produced by excessive generation of reactive oxygen species (ROS) in the inner ear, thus leading to the development of various antioxidants, which act as otoprotective agents. Astaxanthin (ATX) is an interesting candidate in the development of new therapies for preventing and treating oxidative stress-related pathologies, owing to its unique antioxidant capacity. Methods and Results In this study, we aimed to evaluate the potential antioxidant properties of ATX in the inner ear by using the HEI-OC1 cell line, zebrafish, and guinea pigs. Because ATX has poor solubility and cannot pass through round window membranes (RWM), we established lipid-polymer hybrid nanoparticles (LPN) for loading ATX. The LPN enabled ATX to penetrate RWM and maintain concentrations in the perilymph in the inner ear for 24 h after a single injection. ATX-LPN were found to have favorable biocompatibility and to strongly affect cisplatin-induced generation of ROS, on the basis of DCFHDA staining in HEI-OC1 cells. JC-1 and MitoTracker Green staining suggested that ATX-LPN successfully reversed the decrease in mitochondrial membrane potential induced by cisplatin in vitro and rescued cells from early stages of apoptosis, as demonstrated by FACS stained with Annexin V-FITC/PI. Moreover, ATX-LPN successfully attenuated OHC losses in cultured organ of Corti and animal models (zebrafish and guinea pigs) in vivo. In investigating the protective mechanism of ATX-LPN, we found that ATX-LPN decreased the expression of pro-apoptotic proteins (caspase 3/9 and cytochrome-c) and increased expression of the anti-apoptotic protein Bcl-2. In addition, the activation of JNK induced by CDDP was up-regulated and then decreased after the administration of ATX-LPN, while P38 stayed unchanged. Conclusions To best of our knowledge, this is first study concluded that ATX-LPN as a new therapeutic agent for the prevention of cisplatin-induced ototoxicity.

show abstract

Astaxanthin conjugated polypyrrole nanoparticles as a multimodal agent for photo-based therapy and imaging

Cited by 30 publications

References 39 publications

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): assessment of potential otoprotective effects

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN): assessment of potential otoprotective effects

Role of Ultrasound and Photoacoustic Imaging in Photodynamic Therapy for Cancer

Astaxanthin-loaded polymer-lipid hybrid nanoparticles (ATX-LPN) Assessment of potential otoprotective effects

Contact Info

Product

Resources

About